Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Liver disease company Promethera completes €17mm Series B round; raises €6.6mm in debt

Executive Summary

Returning shareholder Vesalius Biocapital has led a €17mm ($23mm) Series B financing for Promethera Biosciences SA NV (hepatic progenitor cell therapeutics and predictive models of liver metabolism). Other Series A investors participating in the round included Société Régionale d'Investissement de Wallonie, Vives-Louvain Technology Fund, Life Science Research Partners, NivelInvest, Financière Spin-off Luxembourgeoise, Universite Catholique de Louvain's tech transfer arm Sopartec, and business angels. First-time backers Boehringer Ingelheim Venture Fund, Shire, Mitsui Global Investment, ATMI, and SambrInvest also joined. In addition, Promethera received €6.6mm in debt funding from the Walloon Region (one of Belgium’s three federal regions) to fund work on Promethera HepaStem, an alternative to liver transplant. The candidate--an injectable suspension of heterologous human adult liver progenitor cells--has been granted orphan drug status in the US and EU and was recently cleared by British and Belgian regulatory officials to begin a Phase I/II trial in children with Crigler-Najjar syndrome or urea cycle disorders.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Venture Financing

Related Companies